Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Up 6.1% in June

Adaptimmune Therapeutics plc (NASDAQ:ADAP) saw a large increase in short interest in June. As of June 15th, there was short interest totalling 4,900,000 shares, an increase of 6.1% from the May 31st total of 4,620,000 shares. Based on an average trading volume of 1,480,000 shares, the short-interest ratio is presently 3.3 days.

Adaptimmune Therapeutics Stock Down 2.9 %

ADAP opened at $1.02 on Thursday. The company’s 50-day moving average price is $1.05 and its 200 day moving average price is $1.10. Adaptimmune Therapeutics has a fifty-two week low of $0.42 and a fifty-two week high of $2.05. The firm has a market cap of $251.76 million, a price-to-earnings ratio of -1.38 and a beta of 2.31.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings results on Wednesday, May 15th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). Adaptimmune Therapeutics had a negative return on equity of 259.68% and a negative net margin of 890.13%. The company had revenue of $5.68 million for the quarter, compared to analyst estimates of $4.40 million. Research analysts anticipate that Adaptimmune Therapeutics will post -0.61 earnings per share for the current year.

Institutional Investors Weigh In On Adaptimmune Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ADAP. Key Client Fiduciary Advisors LLC increased its holdings in shares of Adaptimmune Therapeutics by 6.4% in the 4th quarter. Key Client Fiduciary Advisors LLC now owns 336,620 shares of the biotechnology company’s stock worth $267,000 after acquiring an additional 20,295 shares during the period. Harbor Capital Advisors Inc. grew its position in Adaptimmune Therapeutics by 9.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 147,732 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 13,317 shares during the last quarter. Boulder Hill Capital Management LP bought a new position in Adaptimmune Therapeutics in the 1st quarter worth about $143,000. Twin Focus Capital Partners LLC acquired a new stake in shares of Adaptimmune Therapeutics in the fourth quarter valued at approximately $44,000. Finally, JTC Employer Solutions Trustee Ltd bought a new stake in shares of Adaptimmune Therapeutics during the first quarter valued at approximately $41,000. 31.37% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ADAP. Mizuho reduced their price target on shares of Adaptimmune Therapeutics from $9.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, May 17th. StockNews.com raised Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, June 3rd. Finally, Scotiabank initiated coverage on Adaptimmune Therapeutics in a research report on Thursday, May 30th. They set a “sector outperform” rating and a $3.15 price target on the stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.